Background: Expansion of ART programs in recent years has been promoted as a means to reducing the further spread of new HIV infections. We examined the effect of such an expansion in British Columbia (BC), Canada on all-cause and cause specific mortality among participants in the provincial HIV/AIDS Drug Treatment Program (DTP). Methodology: We analyzed data from participants aged ≥18 in the BC DTP to measure two-year mortality and causes of death from January 1, 2001to December 31, 2012. Deaths were identified through record linkages with the BC Vital Statistics Agency and we used ICD-10 codes for the underlying cause of death. We conducted tests of trend and compared DTP participant characteristics by dividing the study time into two-year time periods for the entire study period. We used Cox proportional hazard models to determine the risk of death for participants who had received ART for at least 3 months. Participants initiating ART in the final two-year period were excluded from the latter analysis. Results: A total of 3933 new participants initiated ART and a total of 8221 received ART during the study period (Table). Overall mortality in the DTP declined from 256/4028 (6.4%) of DTP participants in 2001-2002 to 219/6258 (3.5%) in 2011-2012 (p=0.018 for test of trend). HIV-related deaths decreased (3.8% to 0.9% of DTP participants, p=0.022) and similar decreases were observed in deaths due to chronic liver disease, cardiovascular disease, and suicides (p=0.008, 0.022, and 0.002; respectively). There were no trends with respect to deaths from non-AIDS infections or cancers or respiratory causes. Multivariate models, adjusted for age, gender, history of injection drug-use and adherence to therapy demonstrated that the risk of mortality was independently associated with ART initiation in 2003 – 2004 (adjusted hazard ratio [AHR] 0.74; 95% CI 0.56 – 0.98); 2005 – 2006 (AHR = 0.58; 95% CI 0.42 – 0.80); 2007-2008 (AHR=0.49; 95% CI 0.34 – 0.71) and 2009-2010 (AHR = 0.42; 95% CI 0.25- 0.72) in comparison to 2001 – 2002(reference). Conclusions: We observed decreases in overall mortality and reductions in HIV-related deaths among participants in the BC DTP over the study period. However, we also observed declines in cardiovascular, liver-related deaths and suicides. These changes parallel a secondary expansion of ART in BC which suggests broad clinical benefits to HIV treatment expansion beyond classically-defined HIV-related conditions.